MeSH tree: C06.405.205.663
Eosinophilic esophagitis (EoE), a disorder of the esophagus, is increasingly recognized as a major cause of swallowing difficulties in children and adults. It affects about one in 2,000 people and is part of a spectrum of ...
Oct 24, 2024
0
23
For patients with gastroesophageal reflux disease (GERD), improvement in symptoms is seen with both antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA), but subjective and objective indicators of outcomes ...
Aug 5, 2024
0
29
In one of the first studies of its kind in Japan, Osaka Metropolitan University-led researchers uncovered the incidence and prevalence of the chronic allergic disorder eosinophilic esophagitis, or EoE.
Jul 10, 2024
0
26
The European Union has approved Sanofi and Regeneron's blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (COPD), the French pharmaceutical giant said on Wednesday.
Jul 3, 2024
0
66
Despite high hopes, a drug that wipes out the namesake cell type associated with the disease eosinophilic esophagitis (EoE) doesn't make patients feel better and doesn't reverse tissue damage in their throats.
Jun 27, 2024
0
262
A new position paper from the American College of Allergy, Asthma & Immunology (ACAAI) addresses the safety of administering live vaccines to patients who are currently being treated with dupilumab, a biologic therapy for ...
Jun 11, 2024
0
50
Eosinophilic esophagitis (EoE) is an allergic inflammatory disorder that affects the esophagus, causing distressing symptoms such as difficulty swallowing in adolescents and adults, and vomiting and abdominal pain in children.
Feb 27, 2024
0
44
The U.S. Food and Drug Administration has approved Takeda's Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis (EoE).
Feb 19, 2024
0
47
Children and young adults with allergies or eczema who have difficulty swallowing may have eosinophilic esophagitis. A review published in CMAJ (Canadian Medical Association Journal) provides guidance on how to diagnose and ...
Feb 5, 2024
0
41
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) for the treatment of pediatric patients (aged one to 11 years) with eosinophilic esophagitis (EoE).
Jan 30, 2024
0
53
